BioSante Pharmaceuticals has announced positive results of a new study demonstrating that its calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, BioVant, may serve as a vaccine adjuvant for the development of an effective vaccine against H5N1 avian flu.
The preclinical study's objective was to determine whether BioVant could enhance the body's natural immune response to the H5N1 viral antigen, the cause of bird flu. At the start of the 10-week trial, mice received either the H5N1 antigen alone or in a formulation with BioVant. A booster immunization was administered after two weeks. Results indicated that the administration of a BioVant/H5N1 formulation stimulated production of high titers of H5N1-specific antibodies, and significantly higher than H5N1 alone. Anti-avian flu antibody levels continued to increase over the entire study period, suggesting good duration of immunity.